NEWS

Gwo Xi Stem Cell (TPEx: 6704) today announced the grant of a Taiwan invention patent (Patent No. I897580) titled “Pharmaceutical Composition for Wound Repair and Its Preparation Method.” This patented technology leverages Conditioned Medium of Specific Stem Cell-Derived Factors (SpSF-CM), which have demonstrated significant therapeutic effects in promoting wound healing.

GWOXI Stem Cell showcases its R&D achievements at booth 2R25 during Bio Asia Pacific 2025 in Bangkok, drawing significant attention from international buyers.

GWOXI Stem Cell (TPEx: 6704) today announced the signing of a Memorandum of Understanding (MOU) with Malaysia-based Cell 101 International Sdn Bhd, a company mainly focusing on regenerative medicine. Through this collaboration, the two companies aim to jointly expand their presence in the Asia-Pacific regenerative medicine market.

During the exhibition, Gwo Xi will show the commodification process of four stem cell therapy products, including the safety and efficacy results in clinical trials, alongside applications of its MSC-derived exosomes.  Welcome to join this prestigious international medical event in Japan.

Gwo Xi Stem Cell Applied Technology Co., Ltd., (TPEx: 6704) announced yesterday evening that its stem cell medicine “GXCPC1®”, an allogeneic adipose-derived mesenchymal for the treatment of knee osteoarthritis, has received Phase III clinical trial approval from Taiwan Food and Drug Administration (TFDA) to initiate a Phase III clinical trial. This approval represents an important milestone for the advancement of GXCPC1®.

GWOXI Stem Cell is actively positioning to capture emerging market opportunities by strengthening its intellectual property portfolio, progressing clinical trials of its cell therapy medicines, and enhancing the manufacturing capabilities while applying PIC/S GMP certification, which is also expected to obtain the certification by the end of 2025.

Leveraging its robust patent portfolio and integrated technology capabilities across industry chain, GWOXI (TPEx.: 6704) has successfully advanced multiple innovative technologies from preclinical studies to clinical trials, offering novel therapeutic options for patients.

Gwo Xi Stem Cell’s “Human Adipose-Derived Mesenchymal Stem Cell Exosomes” have obtained INCI name certification as a new cosmetic ingredient.

Gwo Xi Stem Cell’s diabetes therapy candidate “GXIPC1®” has successfully secured patents in the United States, China, and Taiwan.

In preparation for future drug approval and global expansion, Gwo Xi Stem Cell is striving to apply PIC/S GMP certification by the end of October in 2025.